CA3090823A1 - Therapeutic uses of glp1r agonists - Google Patents

Therapeutic uses of glp1r agonists Download PDF

Info

Publication number
CA3090823A1
CA3090823A1 CA3090823A CA3090823A CA3090823A1 CA 3090823 A1 CA3090823 A1 CA 3090823A1 CA 3090823 A CA3090823 A CA 3090823A CA 3090823 A CA3090823 A CA 3090823A CA 3090823 A1 CA3090823 A1 CA 3090823A1
Authority
CA
Canada
Prior art keywords
daily
glp1r
phenyl
agonist
glp1r agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3090823A
Other languages
English (en)
French (fr)
Inventor
Jennifer L.R. Freeman
Maria Carmen Valcarce Lopez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
vTv Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by vTv Therapeutics LLC filed Critical vTv Therapeutics LLC
Publication of CA3090823A1 publication Critical patent/CA3090823A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3090823A 2018-05-08 2019-05-01 Therapeutic uses of glp1r agonists Pending CA3090823A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862668384P 2018-05-08 2018-05-08
US62/668,384 2018-05-08
PCT/US2019/030110 WO2019217165A1 (en) 2018-05-08 2019-05-01 Therapeutic uses of glp1r agonists

Publications (1)

Publication Number Publication Date
CA3090823A1 true CA3090823A1 (en) 2019-11-14

Family

ID=66484210

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3090823A Pending CA3090823A1 (en) 2018-05-08 2019-05-01 Therapeutic uses of glp1r agonists

Country Status (9)

Country Link
US (2) US20210023072A1 (https=)
EP (1) EP3790549A1 (https=)
JP (2) JP2021523877A (https=)
KR (2) KR20210005843A (https=)
AU (2) AU2019266114A1 (https=)
CA (1) CA3090823A1 (https=)
MX (1) MX2020008387A (https=)
SG (1) SG11202007966UA (https=)
WO (1) WO2019217165A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3157525A1 (en) 2019-10-25 2021-04-29 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2021154796A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
US12459954B2 (en) 2020-04-01 2025-11-04 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Crystalline form a of GLP-1 receptor agonist and preparation method therefor
WO2021196951A1 (zh) * 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
TW202210486A (zh) * 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種製備ｇｌｐ—１受體激動劑的方法
EP4213847A4 (en) * 2020-09-21 2024-12-04 vTv Therapeutics LLC AMORPHOUS FORM OF AN ISOQUINOLINE DERIVATIVE
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
WO2022192430A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
PH12023552860A1 (en) 2021-04-21 2024-05-20 Gilead Sciences Inc Carboxy-benzimidazole glp-1r modulating compounds
KR102920994B1 (ko) 2024-05-20 2026-02-02 (주)인벤티지랩 오르포르글리포론 또는 이의 약학적으로 허용되는 염을 포함하는 마이크로 입자 및 이의 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534512A (ja) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
US7727983B2 (en) 2008-03-07 2010-06-01 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
JP5755217B2 (ja) 2009-03-30 2015-07-29 トランステック・ファーマ，エルエルシー 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
WO2011031620A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
EA201491749A1 (ru) * 2012-03-22 2015-01-30 ТРАНСТЕК ФАРМА, ЭлЭлСи Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение
SG10201704716XA (en) * 2013-01-17 2017-07-28 Vtv Therapeutics Llc Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders

Also Published As

Publication number Publication date
KR20210005843A (ko) 2021-01-15
JP2024112903A (ja) 2024-08-21
SG11202007966UA (en) 2020-11-27
JP2021523877A (ja) 2021-09-09
TW202015683A (zh) 2020-05-01
KR20260036616A (ko) 2026-03-17
US20250325536A1 (en) 2025-10-23
AU2025201814A1 (en) 2025-04-03
EP3790549A1 (en) 2021-03-17
MX2020008387A (es) 2020-12-11
US20210023072A1 (en) 2021-01-28
AU2019266114A1 (en) 2020-08-27
WO2019217165A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
US20250325536A1 (en) Therapeutic uses of glp1r agonists
CN101511364B (zh) 用于糖尿病的治疗组合
JP6410600B2 (ja) ２型糖尿病患者における低血糖症の予防
CN107496907A (zh) 诱导ii型糖尿病患者体重减轻或/和防止ii型糖尿病患者体重增加的药物组合产品
AU2014207748B2 (en) Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
US20240245656A1 (en) Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
Mavian et al. Managing type 2 diabetes: balancing HbA1c and body weight
US20180333398A1 (en) Method of weight reduction
TWI918593B (zh) Glp1r激動劑的治療用途
AU2013202988B2 (en) Method of improving liver function
Onge et al. Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes
Moustafa Advances in the management of type 2 diabetes mellitus
CN108236611A (zh) 两种化合物联合在制备治疗糖尿病药物中的用途
ZA200305225B (en) Spaced drug delivery system.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250522

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250922

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250922

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251201

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251201

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251201

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260305